Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 0.80 |
| ▸ | EGLN3 | Q9H6Z9 | 8/20 | 0.80 |
| ▸ | VEGFA | P15692 | 6/20 | 0.80 |
| ▸ | FLT1 | P17948 | 6/20 | 0.80 |
| ▸ | TET3 | O43151 | 1/20 | 0.80 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.80 |
| ▸ | ASPH | Q12797 | 1/20 | 0.80 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.80 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.80 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.80 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.80 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.80 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30239851 | 1.00 | EGLN1 (0.80) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL4367990 | 0.92 | EGLN1 (0.69) | EGLN1EGLN3VEGFAFLT1TET3 | |
| Vadadustat SCHEMBL1920738 | 0.89 | EGLN1 (1.00) | EGLN1EGLN3VEGFAFLT1TET3 | |
| Vadadustat SCHEMBL29405970 | 0.89 | EGLN1 (1.00) | EGLN1EGLN3VEGFAFLT1TET3 | |
| Vadadustat SCHEMBL29357486 | 0.89 | EGLN1 (1.00) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL21390798 | 0.89 | EGLN1 (0.82) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL20711162 | 0.88 | EGLN1 (0.64) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL15164149 | 0.88 | EGLN1 (0.80) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL16728915 | 0.88 | EGLN1 (0.80) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL14308517 | 0.87 | EGLN1 (0.83) | EGLN1EGLN3VEGFAFLT1TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47437-E1 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2019-06-18 | — | — | US | claimed |
| US-20170189387-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT COMPANY, LLC (PR) | 2017-07-06 | — | — | US | claimed |
| US-9598370-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2017-03-21 | — | — | US | claimed |
| US-20160009648-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2016-01-14 | — | — | US | claimed |
| US-20150119425-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT COMPANY, LLC (PR) | 2015-04-30 | — | — | US | claimed |
| US-8940773-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | claimed |
| US-20140045899-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2014-02-13 | — | — | US | claimed |
| US-8598210-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2013-12-03 | — | — | US | claimed |
| US-20130203816-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-8343952-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2013-01-01 | — | — | US | claimed |
| EP-2044005-B8 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT CO LLC (PR) | 2012-12-05 | — | — | EP | claimed |
| US-8323671-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2012-12-04 | — | — | US | claimed |
| EP-2327696-A1 | Prolyl hydroxylase inhibitors and methods of use | Warner Chilcott Company, LLC (PR) | 2011-06-01 | — | — | EP | claimed |
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | claimed |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | claimed |
| EP-2044005-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2008002576-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | claimed |
| US-12478615-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885VEGFA 117/4885 |
| US-12478615-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885VEGFA 117/4885 |
| US-20160009648-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885VEGFA 117/4885 |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885VEGFA 117/4885 |
| US-20130203816-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885VEGFA 117/4885 |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885VEGFA 117/4885 |
| US-20140045899-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885VEGFA 117/4885 |
| US-20150119425-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885VEGFA 117/4885 |
| US-20170189387-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885VEGFA 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.